Literature DB >> 31574515

Lymphomas and Their Microenvironment: A Multifaceted Relationship.

Thomas Menter1, Alexandar Tzankov2.   

Abstract

It has become evident that the microenvironment - lymphocytes, macrophages, fibroblasts as well as the extracellular matrix, cytokines, chemokines, and a plethora of other cells, structures and substances residing in the vicinity of tumor cells - plays an important part in the maintenance of cancer growth and survival. This is also relevant in lymphomas. In this review, we give an outline on the importance of the microenvironment for tumors in general and lymphomas in particular, by highlighting certain basic principles of tumor-microenvironment interaction. The relationship of lymphomas and their microenvironment is multifaceted: lymphoma cells need growth factors and cytokines derived from microenvironmental cells for their sustenance and growth. On the contrary, many lymphomas silence or at least deregulate the immune system to escape recognition and subsequent elimination by immune cells, while giving advantage to suppressive microenvironmental compounds such as M2 polarized macrophages, regulatory T-cells, mast cells, and immunosuppressive fibroblasts. We also give a detailed insight across different lymphoma types to show the variety of tumor-microenvironment interactions. Due to its tremendous importance, the microenvironment has also become a new target for oncologic therapy. The most important finding concerning lymphomas with a focus on immunomodulatory substances is also, therefore, highlighted.
© 2019 S. Karger AG, Basel.

Entities:  

Keywords:  Cytokines; Lymphomas; Macrophages; Microenvironment; T-cells

Mesh:

Substances:

Year:  2019        PMID: 31574515     DOI: 10.1159/000502912

Source DB:  PubMed          Journal:  Pathobiology        ISSN: 1015-2008            Impact factor:   4.342


  7 in total

1.  Tumor cell-activated "Sustainable ROS Generator" with homogeneous intratumoral distribution property for improved anti-tumor therapy.

Authors:  Junjie Liu; Xiu Zhao; Weimin Nie; Yue Yang; Chengcheng Wu; Wei Liu; Kaixiang Zhang; Zhenzhong Zhang; Jinjin Shi
Journal:  Theranostics       Date:  2021-01-01       Impact factor: 11.556

Review 2.  Angiogenesis in Lymph Nodes Is a Critical Regulator of Immune Response and Lymphoma Growth.

Authors:  Lutz Menzel; Uta E Höpken; Armin Rehm
Journal:  Front Immunol       Date:  2020-12-03       Impact factor: 7.561

3.  Lysyl-Oxidase Dependent Extracellular Matrix Stiffness in Hodgkin Lymphomas: Mechanical and Topographical Evidence.

Authors:  Massimo Alfano; Irene Locatelli; Cristina D'Arrigo; Marco Mora; Giovanni Vozzi; Aurora De Acutis; Roberta Pece; Sara Tavella; Delfina Costa; Alessandro Poggi; Maria Raffaella Zocchi
Journal:  Cancers (Basel)       Date:  2022-01-05       Impact factor: 6.639

4.  In-silico probing of AML related RUNX1 cancer-associated missense mutations: Predicted relationships to DNA binding and drug interactions.

Authors:  Hanif Ullah; Baoyun Zhang; Narendra Kumar Sharma; Pierre D McCrea; Yogesh Srivastava
Journal:  Front Mol Biosci       Date:  2022-08-25

5.  SMAD1 promoter hypermethylation and lack of SMAD1 expression in Hodgkin lymphoma: a potential target for hypomethylating drug therapy.

Authors:  Magdalena M Gerlach; Anna Stelling-Germani; Cheuk Ting Wu; Sebastian Newrzela; Claudia Döring; Visar Vela; Anne Müller; Sylvia Hartmann; Alexandar Tzankov
Journal:  Haematologica       Date:  2021-02-01       Impact factor: 9.941

6.  Metabolic activity of extranodal NK/T cell lymphoma on 18F-FDG PET/CT according to immune subtyping.

Authors:  Chae Hong Lim; Sang Eun Yoon; Seok Jin Kim; Junhun Cho; Young Hyeh Ko; Kyung-Han Lee; Won Seog Kim
Journal:  Sci Rep       Date:  2021-03-15       Impact factor: 4.379

Review 7.  Tumor Immune Microenvironment in Lymphoma: Focus on Epigenetics.

Authors:  Daniel J García-Domínguez; Lourdes Hontecillas-Prieto; Natalia Palazón-Carrión; Carlos Jiménez-Cortegana; Víctor Sánchez-Margalet; Luis de la Cruz-Merino
Journal:  Cancers (Basel)       Date:  2022-03-13       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.